CRDF — Cardiff Oncology, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1213037 ·
Last close
$1.20
Market Cap
$93.35M
52W High
$3.31
52W Low
$0.76
ADV30
809,073
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 104,000 | — | -9,615,000 | -9,232,000 | 37,329,000 | 9,197,000 | 10,797,000 |
| Mar 2026 | 41,000 | — | -12,850,000 | -12,345,000 | 49,172,000 | 8,544,000 | 14,463,000 |
| Dec 2025 | 243,000 | — | -7,827,000 | -7,216,000 | 61,884,000 | 17,470,000 | 16,496,000 |
| Sep 2025 | 120,000 | — | -11,974,000 | -11,258,000 | 63,780,000 | 10,135,000 | 14,990,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-37,417,000
Investing CF
$19,183,000
Financing CF
$2,683,000
CapEx
$-18,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.76
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-442,375,000
Inventory
—
Receivables
$191,000
ST Investments
$37,512,000
EBIT TTM
$-47,428,000
Pretax Income TTM
$-44,762,000
Interest Exp TTM
—
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$508,000
EBITDA
$-41,915,000
Free Cash Flow
$-24,304,250
Enterprise Value
$60,069,252
Total Cash
$34,520,000
Total Debt
$457,000
Shares Out
77,795,249
Trailing EPS
$-0.60
Book Value
$0.39
ROE
-94.1%
ROA
-46.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 593,000 | -48,960,000 | -45,851,000 | 61,884,000 | 16,496,000 | 45,388,000 | -37,923,000 |
| Dec 2024 | 683,000 | -48,651,000 | -45,431,000 | 97,190,000 | 14,241,000 | 82,949,000 | -37,693,000 |
| Dec 2023 | 488,000 | -45,412,000 | -41,441,000 | 81,637,000 | 11,898,000 | 69,739,000 | -30,887,000 |
| Dec 2022 | 386,000 | -39,902,000 | -38,704,000 | 116,191,000 | 9,848,000 | 106,343,000 | -33,820,000 |
TTM Snapshot
Revenues TTM
$109,000
NetIncome TTM
$-13,434,000
OpCashFlow TTM
$0
Assets (Latest)
$61,884,000
Forward EPS
$-0.60
Max Pain — expiry 2026-11-20 (volume-derived — Yahoo OI feed degraded)
max pain strike: $1.00 · spot: $1.20 · call volume: 451 · put volume: 18
Expected Move to 2026-11-20:
±$0.63
(52.50%) —
implied range
$0.57 –
$1.83
· ATM straddle on $1.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CGTX | COGNITION THERAPEUTICS INC | $89.24M | $0.94 | — |
| ATRA | Atara Biotherapeutics, Inc. | $84.02M | $8.37 | — |
| BDTX | Black Diamond Therapeutics, Inc. | $104.86M | $1.83 | — |
| PTHS | Pelthos Therapeutics Inc. | $81.35M | $21.25 | — |
| CLLS | Cellectis S.A. | $107.62M | $1.48 | — |
News headlines (Yahoo Finance, 1h cache)
Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement
2026-09-14 12:30 · Yahoo
Cardiff Oncology to Participate in September 2026 Conferences
2026-09-02 11:00 · Yahoo
CRDF: Second Quarter Earnings
2026-08-17 09:47 · Yahoo
Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update
2026-08-11 20:10 · Yahoo
Cardiff Oncology Announces $10 Million Registered Direct Offering to Strengthen Working Capital
2026-07-15 14:54 · Yahoo
Cardiff Oncology Announces $10 Million Registered Direct Offering
2026-07-15 12:00 · Yahoo
Is Cardiff Oncology, Inc. (CRDF) Stock Undervalued Amid Legal Uncertainty and Future Cancer Drug Potential?
2026-06-30 13:06 · Yahoo
CRDF: Phase II Update; Survival Advantage Extended
2026-06-22 11:41 · Yahoo
Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting
2026-06-02 13:06 · Yahoo
Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference
2026-06-01 20:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.